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Abstract 
Anti-citrulline immune responses contribute to rheumatoid arthritis (RA) development, and 
are linked with the expression of HLA-DR molecules that encode the Shared Epitope (SE).  
Immune responses to homocitrulline, a structural analog of citrulline, have been recently 
detected in RA, but their role in RA is unknown. 
The objectives of this study were to examine the specificity of anti-homocitrulline antibodies 
for RA, the dependence of anti-homocitrulline responses on SE-expression, and the cross-
reactivity of responses to homocitrulline and citrulline.  These objectives were addressed in 
RA patients and in SE-expressing DR4tg mice using homocitrulline- and citrulline-rich 
peptides. 
Anti-homocitrulline antibodies occurred specifically in RA.  The SE was associated with the 
development of immune responses to homocitrulline and cross-reactivity to citrulline in 
homocitrullinated peptide-immunized mice.  Anti-homocitrulline and anti-citrulline 
antibodies were cross-reactive in RA patients and DR4tg mice, and the responses to 
homocitrulline- and citrulline-containing peptides were immunologically related.  
 
 
Keywords 
Rheumatoid arthritis, anti-homocitrulline antibodies, anti-citrulline antibodies, cross-
reactivity, Shared Epitope, human patients, mouse model 
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Chapter 1  
1 Rheumatoid arthritis 
1.1 Overview 
Rheumatoid arthritis (RA) is one the most prevalent chronic inflammatory diseases and is 
estimated to affect up to 1% of the population worldwide (1,2).  RA is an autoimmune 
disorder which can often result in irreversible damage to bone and cartilage tissue.  This 
leads to a progressive loss of joint function and often results in disability in RA patients.  
RA is a debilitating disease associated with a decreased quality of life, high economic 
burden (2,3), and an increased rate of mortality compared to the general population (4,5). 
RA is a complex disorder and susceptibility to disease has been reported to be affected by 
various factors.  In RA, similar to other autoimmune diseases, there is a gender bias.  The 
prevalence of RA is greater in women, and gender may also affect the disease course (6).  
Susceptibility to RA is influenced by environmental exposures (7), and especially with 
smoking which has been associated with a heightened incidence of RA (8).  Genetics also 
modify the risk of  RA (9) and genes, such as those coding for major histocompatibility 
antigens (especially Shared Epitope (SE)-encoded HLA-DRB1) can predispose 
individuals to develop RA. 
RA is systemic in nature, and has been shown to affect various organ systems.   The  
joints, skin, cardiovascular system and lungs are a few examples of the tissues that can be 
affected by RA (10).  The mechanism by which RA affects these various tissues is not 
well understood.  Joint inflammation, which is the primary manifestation of RA, often 
involves the large-scale infiltration of leukocytes into the joint tissue and pro-
inflammatory changes to the environment of the joint (11).  These changes are mediated 
by cells of both the innate and adaptive immune system; various immune cells such as 
dendritic cells, macrophages, neutrophils, T and B cells are present in the synovial tissue 
of RA patients (12–14).  Amongst the changes that occur in the synovial tissue are 
increased expression of inflammatory cytokines including TNFα, IL-6, IL-17, and type I 
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interferons (15) as well as matrix metalloproteinases (16), which contribute to the 
degradation of bone and cartilage in RA.  Additionally, phenotypic changes occur in 
joint-resident cell types including fibroblast-like synoviocytes which normally play a role 
in maintaining the synovial fluid (17), and osteoclasts which function in bone resorption, 
thereby promoting the dysfunction and degradation of the joint (11).   
The etiology of RA is currently unknown and thus, targeted treatments for RA are 
unavailable.  Instead, strategies for the treatment of RA employ disease-modifying 
antirheumatic drugs, glucocorticoids and biologics (18).  Some of these therapeutics, 
methotrexate and cortisol for example, are immunosuppressive and have inhibitory 
effects on the immune system.  Other therapeutics have been developed that target 
inflammatory cytokines such as TNFα (19), immune cells including B (20) and T (21) 
cells, as well as immune signaling pathways (22).  These current treatment options for 
RA have broad effects on immune system functions and as a result, are accompanied with 
risks of side-effects including increased risk of infection and cardiovascular disease (23–
25).  To more specifically treat RA, further study of the mechanisms underlying the 
disease is required.  
The disease process in RA is often associated with autoantibodies which predicts disease 
and are believed to participate in RA pathogenesis.  The importance of autoantibodies in 
RA is underscored by the classification of patients as seropositive or seronegative 
depending on the expression of autoantibodies; seropositive and seronegative RA patients 
often differ in disease patterns (ie. disease severity and outcome).  In RA, one of the 
major autoantibodies is rheumatoid factor (RF), an autoantibody which targets IgG and is 
diagnostic for RA.  Anti-citrulline antibodies, which are antibodies that bind to antigens 
containing citrulline, are another class of antibodies that are frequently found in RA 
patients (26–29).  Anti-citrulline antibodies are also a diagnostic biomarker for RA and 
are measured clinically as anti-cyclic citrullinated peptide antibodies (anti-CCP).  Several 
other autoantibody systems have been identified in RA patients, including autoantibodies 
reactive to proteins that have been modified post-translationally by acetylation and by 
formation of malondialdehyde-acetaldehyde adducts (30,31).  Recently, anti-
homocitrulline antibodies have been detected in RA patients and have garnered much 
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interest as a potential biomarker for disease.  Whether anti-homocitrulline antibodies 
have a role in RA pathogenesis remains to be determined. 
1.2 Risk factors for RA  
RA is a multifactorial disorder and the triggers that initiate the disease are poorly 
understood.  A study of monozygotic twins by MacGregor et al. estimated the overall 
heritability of RA (seropositive and seronegative disease) to be 60% (9), indicating that 
genetic risk factors play a substantial role in RA development.  Environmental exposures 
have been reported to be important contributors to RA risk (7,32).  The susceptibility to 
RA is believed to be an interaction between both genetic and environmental risk factors.  
As previously mentioned, RA patients with and without autoantibodies are 
phenotypically different; the complicated nature of RA development is further 
highlighted by the findings that both genetic (33–35) and environmental (32) risk factors 
differ between anti-CCP-positive and anti-CCP-negative RA. 
1.2.1 Smoking 
The most characterized environmental risk factor for RA is smoking.  Meta-analyses by 
Sugiyama et al. (8) and Di Giuseppe et al. (36) have provided evidence that smoking 
increases the incidence of RA.  Moreover, the risk of RA is increased for years even after 
smoking cessation (37).  The mechanisms by which smoking contributes to RA 
development is not clear, though several possibilities have been previously described 
(38).  Smoking induces a pro-inflammatory state that may induce oxidative stress, 
cellular apoptosis and changes in cytokine expression, among many other effects (38).  In 
particular, smoking has been linked to increased TNFα activity (39) which is known to 
mediate RA pathogenesis.   
Notably, smoking has been linked to anti-CCP-positive, but not anti-CCP-negative RA.  
Studies by Kallberg et al. (40) and Linn-Rasker et al. (41) have found associations 
between smoking and expression of anti-CCP (as well as SE-encoded HLA-DRB1), 
which emphasizes the contribution of smoking to the development of anti-citrulline 
immune responses.  This is supported by evidence that smoking promotes the 
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citrullination of self-proteins in the lungs by upregulating the expression of an enzyme 
(peptidylarginine deiminase) that catalyzes protein citrullination  (42,43), as well as the 
finding of citrullinated proteins in lung tissue (44).  Smoking has also been linked to 
protein carbamylation, which could result in the generation of homocitrulline-containing 
antigens (45).  These antigens may help in triggering the development of anti-
homocitrulline antibodies and may also be targets for the autoimmune response.  
However, Jiang et al. did not find an association between anti-homocitrulline antibodies 
and smoking in RA patients that were negative for anti-CCP (46). 
1.2.2 Periodontal disease 
Periodontal disease is a common inflammatory disease that has been associated with anti-
CCP-positive RA.  Both of these diseases share some similar risk factors including 
smoking and expression of HLA-DR4 alleles (47).  Compared to the general population, 
patients with RA are at a higher risk of developing periodontal disease and vice-versa  
(48).  Moreover, RA patients are more likely to develop more severe periodontal disease 
(48).   
Porphyromonas gingivalis is a bacteria that is often found in dental plaque.  P. gingivalis 
has been identified as a major pathogen in periodontal disease and antibodies against this 
pathogen have also been detected in patients with RA (49,50).  Moreover, Kinloch et al.  
demonstrated that α-enolase from P. gingivalis is arthritogenic in a mouse model of RA 
(DR4tg mice) (51).  P. gingivalis expresses several virulence factors that enable the 
pathogen to survive and colonize in host tissue.  Among these are a class of extracellular 
cysteine proteases known as gingipains, which can subvert the host immune response and 
promote inflammation (52).  P. gingivalis also expresses a peptidylarginine deiminase 
which is capable of citrullinating host proteins (53–55), and thereby may initiate anti-
citrulline immune responses in RA-susceptible individuals that express SE-encoded 
HLA-DR molecules. 
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1.2.3 Shared Epitope 
The expression of certain class II MHC molecules play an important role in susceptibility 
to RA.  Genes coding for HLA-DR have been known risk factors since the work of 
Stastny (56,57).  He identified that RA patients shared a common MHC class II haplotype 
(57).  In 1987, Gregersen et al. from the Winchester lab posed the Shared Epitope 
hypothesis to explain the association of several HLA-DRB1 alleles with RA (58).  They 
demonstrated that RA-associated alleles of HLA-DRB1 (including *0401, *0404, *0405, 
*0408, *0413, *0101, *0102, *1402, and *1001) encode for a conserved amino acid 
consensus sequence: QKRAA, QRRAA, or RRRAA (58).  The SE is encoded at 
positions 70-74, located in the third hypervariable region of the N-terminal domain of the 
HLA-DRβ chain (58) and forms the P4 peptide-anchoring pocket of HLA-DR (58,59).  
Alleles encoding for SE-encoded HLA-DR molecules are highly prevalent in RA 
patients, are reported to be expressed in approximately 75% of RA patients (60–62) and 
have also been associated with more severe disease (63). 
The SE is believed to participate in the pathogenesis of RA.  One mechanism by which 
the SE is believed to contribute to RA development is through the presentation of 
citrullinated peptides by antigen presenting cells that express SE-positive HLA-DR 
molecules, leading to the initiation of anti-citrulline immune responses.  The evidence 
that SE-encoded HLA-DR binds to citrullinated peptides was first reported by Hill et al 
(64).  They demonstrated that a citrullinated peptide derived from vimentin bound to SE-
positive HLA-DRB1 molecules encoded by the alleles *0101, *0401 and *0404, but not 
to several SE-negative HLA-DRB1 molecules (64).  This was subsequently confirmed  
by the work of  Scally et al. who reported on crystal structures of HLA-DRB1*0401 
complexed to four citrullinated epitopes derived from vimentin and aggrecan (59).  
Moreover, Huizinga et al. found the SE to be a risk factor for anti-CCP-positive RA, but 
is not associated with anti-CCP-negative disease (65), in keeping with the original 
findings by Hill et al (64).  Additionally, in a mouse model of RA that is transgenic for 
human HLA-DR4 (DR4tg mice), Hill et al. showed that immunization with citrullinated 
fibrinogen induced citrullinated fibrinogen-reactive T and B cell responses as well as 
inflammatory arthritis (66). 
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Besides the involvement in the anti-citrulline immune response, the SE has been shown 
to also act as a signal transduction ligand.  Ling et al., from the Holoshitz lab, showed 
that the SE acts as a ligand that increased production of nitric oxide, resulting in higher 
oxidative stress (67,68).  This was later identified to be mediated through the binding of 
the SE to cell surface calreticulin (69,70).  This signalling event has been shown to have 
various consequences that may contribute to RA pathogenesis.  Almeida et al. from the 
same group, demonstrated that SE-activated signalling in dendritic cells induced a Th17-
polarizing response (71), which is associated with autoimmunity.  In another study by 
this group, Holoshitz et al. reported that SE-mediated signalling is able to induce 
osteoclastogenesis and promote the degradation of bone tissue (72).  Recently, they also 
showed that the SE is associated with spontaneous skeletal bone damage in DR4tg mice 
(73).  The observations of Holoshitz and colleagues suggest that the SE may be involved 
in the development of arthritis independent of its role in antigen presentation.   
1.2.4 Other genetic risk factors 
In addition to genes coding for HLA-DR with the SE, other genetic risk factors have also 
been associated with RA susceptibility.  One of these non-HLA risk factors is PTPN22, 
which encodes for a tyrosine phosphatase that is expressed by leukocytes and functions in 
immune system signalling; a polymorphism of PTPN22 has been associated with an 
increased risk for developing anti-CCP-positive RA (34,74,75).  PADI4, which encodes 
for an enzyme that participates in protein citrullination, is another risk locus for RA 
development (75,76) and has been associated with radiographic damage (77).  Recently, a 
genome-wide association study performed by Okada et al. identified approximately 100 
loci that modify the susceptibility to RA (78).  Many of these loci contain genes related to 
immune system functions including T cell signalling, cytokines such as TNFα and IL-6, 
and also members of the Janus kinase signalling family (78).  Nonetheless the SE is the 
most important risk factor for RA (79). 
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1.3 Autoantibodies in RA  
The breakdown of immunological tolerance to endogenously expressed proteins is often 
the first step in the development of autoimmunity.  In RA, the disease process results in 
the production of autoantibodies and the detection of these antibodies is therefore 
important for RA diagnosis.  As noted (in 1.1), the presence of autoantibodies in patients 
is often a predictor for disease severity in RA.  Thus screening for these antibodies is 
crucial for the early identification of RA, allowing for therapeutic intervention prior to 
the development of potentially irreversible tissue damage.  Further studies of 
autoantibody systems in RA is important to understand the mechanisms leading to the 
pathogenesis of RA and additionally, to provide clinically relevant information to aid in 
the treatment of this disease. 
1.3.1 Rheumatoid factor 
RFs were the first autoantibodies that were associated with RA and were initially 
described in the 1940’s when Waaler (80) and Rose et al. (81) demonstrated that sera 
from RA patients could promote the agglutination of sheep red blood cells that were 
sensitized with rabbit IgG.  RFs are autoantibodies (of several isotypes) that recognize the 
Fc portion of human IgG (82), and were included in the diagnostic criteria for RA in 
1987 (83).  RFs have been shown to be present in approximately 50-65% of patients with 
early RA (27,84) and in up to 90% of patients with longstanding disease (84,85).  
However, RFs are not specific for RA; RFs have been shown to be found in patients with 
other autoimmune diseases as well as in healthy individuals (30,84,86).  Despite the 
evidence that RFs are not specific for RA, they have been associated with RA activity.  
RFs have been reported to predict the development of RA (87) and have been associated 
with radiographic progression (88,89).   
1.3.2 Anti-citrulline antibodies 
Anti-citrulline antibodies (a general term for anti-citrullinated protein/peptide antibodies; 
ACPA) are highly characteristic of and are specific for RA.  Citrullination is a normal 
post-translational process that involves the enzymatic conversion of positively charged 
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arginine residues into non-charged citrulline residues (Figure 1.1A).  The importance of 
this arginine-to-citrulline modification for the binding of peptides to SE-encoded HLA-
DR molecules was first reported in the aforementioned study of the SE by Hill et al. (64) 
and was corroborated by the study of Scally et al (59).  The process of citrullination is 
mediated by the peptidylarginine deiminase (PAD) enzyme family, of which five 
isozymes are expressed in humans (90).  PAD enzymes are expressed ubiquitously and 
can be found in many different cell and tissue types.  PAD2 and PAD4 in particular are 
expressed by cells of the immune system (90) and have been demonstrated to be in RA 
synovial tissue (91–93).  It is unknown whether these two PAD isozymes contribute 
equally or if one of them is more important in the generation of citrullinated antigens in 
RA.  The antigen(s) responsible for driving inflammation in RA remains unknown, 
though several candidate citrullinated autoantigens have been identified in RA joints 
including fibrinogen (94), vimentin (95,96), type II collagen (97) and α-enolase (92,98). 
Schellekens et al. were the first to identify that citrulline was the target of anti-citrulline 
antibodies (99).  Prior to this report, these RA-associated autoantibodies were described 
as anti-perinuclear factor (100), anti-keratin antibodies (101) and anti-filaggrin antibodies 
(102).  As previously noted, anti-citrulline antibodies are commonly measured clinically 
using cyclic citrullinated peptide(s) (CCP) and have been included as a diagnostic marker 
for RA alongside RF (103).  These antibodies are detected in approximately 70% of RA 
patients and are almost 100% specific for RA (26,104,105).  Further, anti-CCP have been 
shown to precede the onset of arthritic symptoms as well as predict RA development 
(29,106,107).  Anti-citrulline antibodies are also believed to be arthritogenic because RA 
patient sera (108) and purified human IgG anti-citrulline antibodies (109) have been 
reported to induce arthritis in young FcγRIIB-deficient mice. 
1.3.3 Anti-homocitrulline antibodies 
Anti-homocitrulline antibodies (a general term for anti-homocitrullinated protein/peptide 
antibodies; AHCPA), also known as anti-carbamylated protein antibodies (anti-CarP), are 
a family of antibodies that were reported to be associated with RA in 2010.  Turunen et 
al. showed that the immunization of rabbits with homocitrullinated albumin and type I 
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Figure 1.1. Citrullination and homocitrullination.  The post-translational conversion 
of arginine to citrulline (citrullination; A) and the conversion of lysine to homocitrulline 
(homocitrullination; B).  The chemical structures of homocitrulline and citrulline are 
similar.  The difference between these residues is that homocitrulline possesses an 
additional carbon in its side chain (red arrow). 
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collagen induced RA-associated autoantibodies (110).  Also, evidence that homocitrulline 
may play a role in RA pathogenesis was reported by Mydel et al., who demonstrated that 
homocitrulline-containing peptides derived from filaggrin induced inflammatory arthritis 
in mice (111).  The susceptibility to arthritis in these mice varied depending on the strain, 
suggesting that the susceptibility to arthritis is influenced by the MHC class II haplotype 
(111). 
Anti-homocitrulline antibodies are frequently detected in RA patients and have garnered 
interest as a potential biomarker for RA.  However, the anti-homocitrulline immune 
response remains poorly understood in RA.  The genetic factors (eg. HLA-DR) that 
contribute to this response have not been characterized.  The in vivo antigenic target of 
these antibodies is unknown and as a consequence, different systems of homocitrullinated 
antigens are currently being used to screen for these antibodies (mentioned in further 
detail below).   
1.3.3.1 Homocitrulline 
Anti-homocitrulline antibodies target proteins/peptides that have undergone a post-
translation process known as homocitrullination (also called carbamylation).  In this 
process, the ε-amino group of a peptidyl-lysine residue is modified to generate 
homocitrulline (45) (Figure 1.1B).  Homocitrulline shares a similar chemical structure 
with citrulline.  Both homocitrulline and citrulline are polar, neutrally-charged amino 
acids and both of these residues possess an ureido functional group.  The only difference 
between citrulline and homocitrulline is that the homocitrulline side chain is extended by 
an additional carbon. 
The process of homocitrullination is mediated chemically by cyanate, which can be 
generated in the body through the spontaneous degradation of urea; cyanate and urea 
exist in equilibrium in solution (45).  Thus, low levels of cyanate are present under 
physiological conditions.  Thiocyanate is a metabolite that is elevated in the serum of 
smokers (112), and the oxidation of thiocyanate is also able to produce cyanate (45).  The 
oxidation of thiocyanate has been associated with the activity of myeloperoxidase (45), 
which is an enzyme that is abundantly expressed in neutrophils and monocytes.  In a 
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mouse model of peritonitis (inflammation of the peritoneum), Wang et al. reported higher 
levels of homocitrullinated proteins in wild-type mice compared to myeloperoxidase-
deficient mice (45) and there is also evidence that myeloperoxidase and homocitrulline 
are found in the synovial tissue of RA patients (93).  These observations demonstrate an 
association between inflammation, homocitrullination and RA. 
1.3.3.2 Anti-carbamylated fetal calf serum antibodies 
Anti-homocitrulline antibodies were first detected in RA patients in 2011 by Shi et al. 
who screened for antibodies reactive to carbamylated fetal calf serum (anti-CarP-FCS) 
(113).  Fetal calf serum is a mixture of proteins of bovine origin, thus CarP-FCS likely 
does not correspond to in vivo homocitrullinated antigens in RA patients.  However, 
CarP-FCS remains a commonly used antigen for the detection of anti-homocitrulline 
antibodies. 
The prevalence of anti-CarP-FCS in RA patients is estimated to be 30-45% (46,113–115).  
These antibodies are mainly found in patients who are also positive for anti-CCP, but can 
also be detected in a small proportion of anti-CCP-negative RA patients (46,113).  
Similar to RF and anti-CCP, anti-CarP-FCS can be present in individuals prior to the 
onset of RA (116,117), and are also predictive of more severe disease outcomes 
(113,118).  Anti-CarP-FCS have been shown to also be expressed in other inflammatory 
arthritides and connective tissue diseases  (114,119–122).  This has led to the notion that 
anti-CarP-FCS may be a biomarker of inflammation rather than being specific for RA, as 
proposed by Reed et al (123).  However, the expression of anti-CarP-FCS in other 
inflammatory (non-rheumatologic) conditions is yet to be examined.  
1.3.3.3 Anti-homocitrullinated fibrinogen antibodies 
Homocitrullinated fibrinogen as a candidate protein antigen for anti-homocitrulline 
antibodies was first studied by Scinocca et al. (124), based on the evidence that 
citrullinated forms of fibrinogen were located in RA synovial tissue (94) and are the 
target of anti-citrulline antibodies in RA patients (28,94,125).  Scinocca et al. reported 
that human fibrinogen is accessible to homocitrullination; 89 of 103 lysines (in 
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fibrinogen) were able to undergo homocitrullination in vitro (124).  Anti-
homocitrullinated fibrinogen antibodies have been shown to exist as several isotypes in 
RA patients.  IgG anti-homocitrullinated fibrinogen antibodies were reported to be the 
predominant isotype, having been found in approximately 30-45% of RA patients 
(124,126) as well as in up to 20% of first-degree relatives of RA patients (126).  The 
prevalence of IgM and IgA anti-homocitrullinated fibrinogen antibodies were noted to be 
lower, and were present in 20% and 7% of RA patients respectively (126).  In addition, 
Scinocca et al. reported that anti-homocitrullinated fibrinogen antibodies were highly 
specific for RA as these antibodies were not detected in patients with systemic lupus 
erythematosus nor in patients with psoriatic arthritis (124). 
1.3.3.4 Antibodies to other homocitrulline-containing antigens 
Since anti-homocitrullinated antibodies have been described, several other 
homocitrullinated peptide antigens have also been used for antibody screening.  So far, 
homocitrulline-containing peptides derived from proteins that are commonly found in the 
synovial tissue of RA patients have been examined, including vimentin (127), collagen 
(128), and α-enolase (123).  The frequency of IgG antibodies to these homocitrullinated 
peptides in RA patients is approximately 20-35% (123,127,128). 
1.4 Immunological relatedness of citrulline and 
homocitrulline 
Citrulline and homocitrulline are structurally similar amino acids and the idea that these 
amino acids are immunologically related was first brought up by Turunen et al. in 2010.  
They were the first to show that a commonly employed commercial antibody (also 
known as the Senshu antibody) for the detection of citrulline, also recognized 
homocitrulline (110).  They also found anti-citrulline antibodies following the 
immunization of rabbits with homocitrullinated proteins (110).  In contrast, Mydel et al. 
found that antibodies to homocitrulline and citrulline in mice were specific for the 
homocitrullinated or citrullinated peptide used for immunization (111).   
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Human studies have shown that anti-homocitrulline antibodies and anti-citrulline 
antibodies are often co-expressed in RA (46,113,114,123).  RA patients frequently 
express the SE (60–62), which has been shown to accommodate citrulline and 
homocitrulline similarly (124).  This event could initiate citrulline-specific, 
homocitrulline-specific or cross-reactive immune responses in RA.   
1.4.1 Anti-citrulline and anti-homocitrulline antibody cross-
reactivity in RA patients 
Several studies have examined the cross-reactivity of anti-citrulline and anti-
homocitrulline antibodies in RA patients (113,123,124,127–129), with varying degrees of 
cross-reactivity between these antibodies being reported.  The differences in the observed 
cross-reactivity between anti-citrulline and anti-homocitrulline antibodies have led to the 
two opposing views that these antibodies constitute a single family of antibodies that are 
reactive to both citrulline and homocitrulline (cross-reactive), or that anti-citrulline and 
anti-homocitrulline antibodies are distinct antibody systems (non-cross-reactive). 
The first studies on the cross-reactivity of anti-citrulline and anti-homocitrulline 
antibodies in RA patients were conducted by Shi et al., using citrullinated and 
homocitrullinated forms of FCS (113) and later, fibrinogen (129).  Two studies that were 
conducted by Shi et al. found differing levels of cross-reactivity between anti-citrulline 
and anti-homocitrulline antibodies, depending on the antigens that they used (113,129).  
In one study, they reported that anti-CCP and anti-CarP-FCS were not cross-reactive to 
citrullinated and homocitrullinated FCS (113).  In another study, they used 
homocitrullinated fibrinogen and they showed that antibodies to this antigen were cross-
reactive in some RA patients because the binding of these antibodies to homocitrullinated 
fibrinogen could be inhibited by citrullinated fibrinogen (129).  Using the same antigen 
(fibrinogen) and method, Scinocca et al. also showed cross-reactivity of anti-
homocitrullinated fibrinogen antibodies, but in the majority of RA patients that they 
examined (124).  
A limitation of these studies however, was the use of modified (homocitrullinated or 
citrullinated) proteins as a target of anti-citrulline and anti-homocitrulline antibodies.  As 
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reported by Scinocca et al. (124), proteins such as fibrinogen differ in the number of 
arginine and lysine residues, and this could result in different numbers of citrulline or 
homocitrulline residues following each modification.  Differences in the position of 
citrulline and homocitrulline in the protein sequence could also affect citrulline and 
homocitrulline cross-reactivity because the backbone surrounding these residues are 
likely to be different and this could influence antibody binding.  Thus, more recent 
studies on the cross-reactivity of anti-citrulline and anti-homocitrulline antibodies have 
utilized citrulline- and homocitrulline-containing peptides (123,127,128) instead of 
proteins.  Juarez et al. (127) and Turunen et al. (128) have found only partial overlap in 
the specificities of antibodies to citrullinated and homocitrullinated peptides of vimentin 
and collagen, whereas Reed et al. (123) showed significant cross-reactivity using a 
peptide of α-enolase.  Thus, the evidence of the relatedness of anti-citrulline and anti-
homocitrulline antibodies is controversial, and the identity of these antibodies as a single 
(cross-reactive) or discrete (non-cross-reactive) antibody families remains unresolved. 
1.4.2 Anti-citrulline and anti-homocitrulline antibody cross-
reactivity in animal models 
Evidence of cross-reactive citrulline and homocitrulline immune responses in 
experimental animal models has been explored by only two groups.  Turunen et al. 
examined the cross-reactivity of citrulline and homocitrulline immune responses in 
rabbits  (110,130).  They showed that rabbits that were immunized with 
homocitrullinated proteins (albumin and type I collagen) generated antibodies to the 
proteins used in immunization as well as antibodies to citrullinated antigens, including 
CCP, citrullinated vimentin and citrullinated telopeptides of type I and type II collagen 
(110,130).  In some of these rabbits, the antibody binding to citrulline-containing 
peptides of type I collagen could be inhibited by similar peptides which contained 
homocitrulline residues instead of citrulline (110,130).  Similarly, the immunization of 
rabbits with citrullinated peptides (derived from type I and type II collagen) generated 
antibodies to citrullinated and homocitrullinated peptides  (130).  Thus these studies by 
Turunen et al showed that anti-citrulline and anti-homocitrulline antibodies are cross-
reactive. 
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Mydel et al. examined the cross-reactivity of anti-homocitrulline and anti-citrulline 
immune responses in mice (111).  They showed that mice immunized with a 
homocitrullinated filaggrin peptide developed antibodies to this homocitrullinated 
peptide, but which did not cross-react with its citrullinated counterpart.  These mice also 
developed arthritis when given intra-articular injections of citrullinated filaggrin peptide 
despite not having antibodies to this antigen.  The mechanism underlying the induction of 
arthritis in these mice is not known. 
1.5 Rationale, hypothesis and objectives 
RA is associated with immune responses to citrulline and more recently, with anti-
homocitrulline immune responses.  Homocitrulline is structurally similar to citrulline, 
thus these amino acids may be recognized similarly by the immune system.   
In RA patients, studies on the relatedness of anti-citrulline and anti-homocitrulline 
antibodies have reported discrepant findings on the cross-reactivity of these antibodies.  
The degree of cross-reactivity has been found to differ depending on the antigen of study 
(113,123,124,127–129).  In experimental animal models, cross-reactive anti-citrulline 
and anti-homocitrulline immune responses have been shown in rabbits (110,130) but not 
in mice (111).  Thus the relatedness of the anti-citrulline and anti-homocitrulline immune 
response remains controversial. 
In addition, immune responses to citrulline have been associated with the SE, the 
strongest genetic risk factor for RA (79).  SE-encoded HL-DR molecules have been 
reported to bind to citrulline-containing peptides, resulting in T and B cell responses to 
these antigens in DR4tg mice (66).  It is unknown whether the SE plays a similar role in 
the development of anti-homocitrulline immune responses. 
This study attempts to address some of these issues using RA patients and in a mouse 
model of RA (DR4tg mice).  We examined the anti-homocitrulline and anti-citrulline 
immune response using a synthetic homocitrulline-rich peptide, HomoCitJED, and its 
citrulline-containing counterpart, CitJED.  These peptides share the same number of 
homocitrulline or citrulline residues and share the same peptide backbone. 
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The hypothesis of this study is that the anti-homocitrulline and anti-citrulline immune 
responses are related and are specific for RA.  Anti-homocitrulline and anti-citrulline 
antibodies are cross-reactive and their expression is dependent on the SE. 
To test this hypothesis, the objectives of this study are to examine: 
i) The frequency and specificity of antibodies to a homocitrulline-containing 
peptide (HomoCitJED) and its citrulline-containing counterpart (CitJED) in 
RA patients. 
ii) The cross-reactivity of these antibodies to HomoCitJED and CitJED in RA 
patients. 
iii) The development of T and B cell responses to HomoCitJED in (SE-positive) 
DR4tg mice and (SE-negative) wildtype B6 mice following immunization 
with HomoCitJED. 
iv) The cross-reactivity of the immune responses in HomoCitJED-immunized 
DR4tg and B6 mice. 
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Chapter 2  
2 Relatedness of antibodies to peptides containing 
homocitrulline or citrulline in patients with rheumatoid 
arthritis 
This chapter is under review for publication in The Journal of Rheumatology. 
2.1 Introduction 
Rheumatoid arthritis (RA) is an inflammatory autoimmune disorder that predominantly 
affects the joints and is specifically associated with anti-citrullinated protein/peptide 
antibodies (ACPA) (1–4).  Recently, anti-homocitrullinated protein/peptide antibodies 
(AHCPA), also known as anti-carbamylated protein antibodies (anti-CarP) have been 
identified in RA patients (5–9).  Both ACPA and AHCPA can occur prior to disease 
onset (6,10,11) and are predictive of more severe disease (8,12).  ACPA have been 
demonstrated to be arthritogenic (13,14); the role of AHCPA in RA pathogenesis is 
unknown. 
ACPA and AHCPA target citrullinated and homocitrullinated antigens, which arise from 
the post-translational modification of arginine and lysine respectively.  Citrulline and 
homocitrulline have identical chemical structures, except homocitrulline has an additional 
carbon (15).  Studies show that ACPA can detect proteins containing homocitrulline 
(5,16).  However, the degree of cross-reactivity of ACPA for homocitrullinated proteins 
varied between the studies.   These discrepancies may be due to proteins having different 
numbers and locations of citrulline and homocitrulline, as we have previously reported 
for fibrinogen (5), potentially resulting in different peptide antigens.  Studies using 
citrulline and homocitrulline-containing peptides with the same backbone were 
inconclusive because the affinity of antibodies to citrullinated and homocitrullinated 
peptides were not investigated (17–19).    
In this study, we used a synthetic citrulline-rich peptide, JED (referred to here as CitJED) 
and its homocitrullinated counterpart (HomoCitJED).  These peptides have a high 
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proportion of citrulline and homocitrulline residues (9/18) rendering immune reactivity to 
the backbone unlikely.  Although not derived from an endogenously expressed 
autoantigen, we showed that CitJED captures clinically relevant antibody reactivities 
from RA patients (anti-cyclic citrullinated peptide and anti-citrullinated fibrinogen 
antibodies) (5).  Herein we employed CitJED and HomoCitJED to examine the 
expression, relatedness and relative affinity of antibodies to citrullinated and 
homocitrullinated peptides in RA patients.   
2.2 Materials and methods 
2.2.1 Study population 
Serum samples were collected from healthy subjects, and from RA patients attending a 
tertiary care Rheumatology clinic at St. Joseph’s Health Care London (SJHC; London, 
ON, Canada).  All RA patients (n=137) satisfied the American College of Rheumatology 
2010 criteria for RA (20) and all were treated with disease-modifying antirheumatic 
drugs.  The swollen joint count in RA was determined by the treating rheumatologist who 
performed a 64 joint examination; only swollen joints attributed to active RA were 
included in the count.  RA patients without joint swelling were considered to be in 
remission.  Demographic, serological and clinical characteristics of RA patients are 
summarized in Table 2.1. Healthy subject serum samples (n=51) were collected from 
accompanying individuals who were unrelated to the RA patients, and from staff 
members at SJHC or The University of Western Ontario (London, ON, Canada).  Healthy 
subjects were 65% female with a median age of 45 years (range 21-74).  Healthy subjects 
did not have autoimmune disease, and were excluded from the study if they had a history 
of joint symptoms. 
Systemic Lupus Erythematosus (SLE) and Psoriatic Arthritis (PsA) patients were 
previously described (5).  SLE patient serum samples were collected from patients 
attending SJHC (n=37).  All of these patients satisfied the American College of 
Rheumatology criteria for SLE (21).  SLE patients were 89% female with a mean age of 
53 years (range 24-81).  Of the 37 SLE patients, 2 also had inflammatory arthritis and one   
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Table 2.1. Demographic, serological and clinical characteristics of RA patients  
 RA Patients (n=137) 
Demographic Features  
     No. (%) Female 100 (73) 
     Age, median (range) years 59 (19-82) 
     Disease duration, median (range) years   4 (0.17-51) 
IgG anti-CCP2  
     No. positive (%) 87 (64) 
     Mean concentration, (range) (Units/mL) 121.3 (6.0-475.0) 
Rheumatoid Factor  
     No. positive (%) 83 (61) 
Smoking Historya  
     No. (%) with smoking history 81 (61) 
Joint Symptomsb  
     No. (%) with joint swelling 57 (47) 
     Average No. of swollen joints 7.2 
a Data available for 132 RA patients  
b Data available for 121 RA patients; Joint swelling was determined by the treating 
rheumatologist and was associated with active RA disease activity 
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had secondary Sjögren’s syndrome.  PsA patient sera were collected from SJHC (n=10) 
or were provided by Dr. Dafna Gladman from the Centre for Prognosis Studies in the 
Rheumatic Diseases, Toronto Western Hospital (n=27), all of whom either met CASPAR 
criteria for PsA (22) or were diagnosed as having PsA by a rheumatologist in a 
specialized PsA clinic.  PsA patients were 46% female with a mean age of 53 years 
(range 36-82).  This study was approved by the Human Ethics Committee of The 
University of Western Ontario (London, ON, Canada) according to the Declaration of 
Helsinki (REB #09684E and #100868). 
2.2.2 Antigens 
The following peptide antigens were used for antibody assays: i) JED, referred to here as 
CitJED, a proprietary synthetic, cyclic peptide, 18 amino acids in length with 9 residues 
of citrulline (5,23,24); and ii) Homocitrullinated JED (HomoCitJED), identical to CitJED 
except that all 9 citrulline residues were replaced with homocitrulline.  The sequences of 
both peptides were confirmed by mass spectrometry and the purity was greater than 85%, 
as provided by the supplier. 
CitJED and HomoCitJED were synthesized by Creative Peptides (Shirley, NY, USA).  
CitJED and HomoCitJED were dissolved in 15% HCl in sterile distilled water for direct 
Enzyme-Linked Immunosorbent Assay (ELISA) and for inhibition ELISAs.  
HomoCitJED was dissolved in 15% HCl in sterile distilled water to increase its solubility.  
Although water soluble, CitJED was also dissolved in 15% HCl in order to compare the 
antibody-binding properties of CitJED and HomoCitJED.  This treatment did not alter 
peptide structure as determined by mass spectrometry and ELISA (data available upon 
request). 
2.2.3 Antibody assays 
Human sera were tested for expression of IgG anti-CitJED and IgG anti-HomoCitJED 
using direct antibody-binding ELISA.  The protocol was adapted from Hill et al (4).  
Wells of ELISA plates (Nunc Maxisorp, VWR) were coated overnight at 4˚C with 2 μg 
of peptide (20 μg/mL; CitJED or HomoCitJED) per well in carbonate coating buffer, pH 
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9.6.  The wells were washed with wash buffer (PBS, 0.05% Tween) and blocked for 30 
minutes at room temperature (RT) with 200 μl of blocking buffer (PBS, 0.1% BSA).  
Serum samples were diluted 1:100 or higher in diluent (PBS, 0.1% BSA, 0.05% Tween).  
100 μl of diluted sera were added to duplicate wells and incubated for 30 minutes at RT.  
After washing, 100 μl of biotin-conjugated goat anti-human IgG (1:8000; Sigma) and 
streptavidin horseradish peroxidase polymer (1:4000; Abcam) were added for 30 minutes 
at RT.  After washing again, 100 μl of 3,3’,5,5’-Tetramethylbenzidine substrate (Sigma) 
was added to the wells and incubated for 10 minutes at RT.  The reaction was stopped 
with 50 μl of 1M H2SO4 and the absorbance was determined at 450 nm.   
Anti-CitJED and anti-HomoCitJED antibody concentrations in tested serum samples 
were determined by comparison to a reference serum sample, which was positive for both 
antibodies.  These concentrations were quantified in Arbitrary Units/mL (AU/mL).  The 
cut-off values for positive anti-CitJED and anti-HomoCitJED expression were 3.8 
AU/mL and 25.3 AU/mL respectively.  The cut-off values represent the mean antibody 
concentration of healthy subjects + 2 standard deviations.  Anti-CitJED and anti-
HomoCitJED concentrations are reported as an average of at least 3 repeat determinations 
(<20% inter-assay variation).  The number of patients with antibody levels greater than 
twice the upper limit of normal were also reported, similar to ACR criteria (20).  IgG 
anti-CCP2 and IgM Rheumatoid Factor (RF) concentrations were determined by 
Pathology and Laboratory Medicine, London Health Sciences Centre (London, ON, 
Canada) or by our laboratory using anti-CCP2 (Euroimmun) or RF (Inova Diagnostics) 
ELISA kits. 
Cross-reactivity of anti-CitJED and anti-HomoCitJED was determined by inhibition 
ELISA.  The protocol was adapted from Scinocca et al (5).  Various amounts of soluble 
peptide in diluent were incubated with diluted RA patient sera for 1 hour at RT prior to 
addition to ELISA wells coated with CitJED or HomoCitJED and carried out as 
described for direct antibody-binding ELISA.  Inhibition assays were repeated at least 2 
times for each patient.  Sera were selected for inhibition ELISA based on antibody 
concentration which were a minimum of 10 AU/mL for anti-CitJED and 70 AU/mL for 
anti-HomoCitJED.  These minimum concentrations were required to obtain a dose-
33 
 
dependent, reproducible inhibition.  Anti-CitJED and anti-HomoCitJED were considered 
as cross-reactive if inhibition with the non-cognate peptide was equal or higher than 50% 
at any inhibiting peptide concentration. 
2.2.4 Statistical analysis 
Graphpad Prism 6.0 software was used for data analysis.  Fisher’s exact test was used for 
comparison of categorical values.  The Kruskal-Wallis Test with Dunn’s multiple 
comparison  was used to compare expression of anti-CitJED and anti-HomoCitJED in 
RA patients to healthy subjects, SLE patients, and PsA patients (p<0.005 was considered 
significant).  Correlation between anti-CitJED and anti-HomoCitJED expression was 
tested using Spearman’s correlation.  Two-way ANOVA with Bonferonni correction was 
used for statistical analysis of inhibition experiments (p<0.01 was considered significant).  
2.3 Results 
2.3.1 Occurrence of anti-CitJED and anti-HomoCitJED antibodies 
in RA patients, healthy subjects and patients with SLE or 
PsA 
IgG antibodies reactive to CitJED and HomoCitJED were assessed in 137 RA patients, 
51 healthy subjects, 37 SLE patients, and 37 PsA patients.  Anti-CitJED levels were 
significantly higher in RA patients compared to other groups (p<0.0001; Figure 2.1A).  
Anti-CitJED was expressed in 69/137 (50%) of RA patients; 54/69 (78%) of these RA 
patients had anti-CitJED levels greater than twice the cut-off.  Anti-CitJED was detected 
in 2/51 (4%) of healthy subjects, and was not detected in patients with SLE or PsA.  Anti-
HomoCitJED was also detected at elevated levels in RA patients compared to other 
groups (p<0.0001; Figure 2.1B).  Of the RA patients, 78/137 (57%) were positive for 
serum anti-HomoCitJED with 49/78 (63%) of these anti-HomoCitJED positive RA 
patients having antibody levels greater than twice the cut-off.    In contrast, only 4/51 
(8%) of healthy subjects had low levels of anti-HomoCitJED.  Anti-HomoCitJED was 
not found in PsA, but was detected in 1 patient with SLE with a concentration of 162.6 
AU/mL.  This SLE patient was felt to have an overlap connective tissue disease with 
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Figure 2.1. Serum anti-CitJED and anti-HomoCitJED levels are increased in RA patients.  Serum anti-CitJED (A) and anti-
HomoCitJED (B) were screened in RA patients (n=137), healthy subjects (n=51), SLE patients (n=37) and PsA patients (n=37).  Cut-
off values were 3.8 AU/mL for anti-CitJED and 25.3 AU/mL for anti-HomoCitJED. Grey bars represent the median concentration.  
Number and percentages of positive sera, median concentrations and the interquartile range are shown below the respective group.
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features of both SLE and RA given that this patient had erosive inflammatory arthritis 
and was also anti-CCP2 positive.  These results indicate that anti-CitJED and anti-
HomoCitJED antibodies are frequently present at high concentrations in RA patients, and 
infrequently found in healthy subjects, SLE or PsA patients. 
2.3.2 Co-expression of anti-CitJED and anti-HomoCitJED 
antibodies in RA patients 
Forty-eight of 137 (35%) RA patients were negative for both anti-CitJED and anti-
HomoCitJED, while 58/137 (42%) of RA patients were positive for both antibodies.  
Eleven of 137 (8%) and 20/137 (15%) of RA patients were single positive for anti-
CitJED or anti-HomoCitJED, respectively.  Thus, anti-CitJED and anti-HomoCitJED 
have a concordance of 77%.  A strong correlation was found in the levels of serum anti-
CitJED and anti-HomoCitJED (Spearman rs=0.6676, p<0.0001; Figure 2.2) and we 
observed an association between anti-CitJED and anti-HomoCitJED antibody expression 
with an odds ratio of 12.65 (95% CI: 5.52-29.00).  The levels of anti-HomoCitJED in 
patients with anti-CitJED and anti-HomoCitJED were significantly greater compared to 
patients who had anti-HomoCitJED alone (p<0.001, data not shown).  
The expression of anti-CitJED and anti-HomoCitJED in relation to anti-CCP2 is shown 
in Figure 2.3.  Eighty-seven of 137 (64%) RA patients were positive for anti-CCP2.  Of 
the anti-CCP2 positive RA patients, 53/87 (61%) expressed anti-CitJED and 58/87 (67%) 
were positive for anti-HomoCitJED.  In the 50 RA patients who lacked anti-CCP2, 16/50 
(32%) had anti-CitJED and 20/50 (40%) had anti-HomoCitJED.  Only 6/137 (4%) of RA 
patients were positive for anti-HomoCitJED and negative for both anti-CitJED and anti-
CCP2; Only 1 of these patients had anti-HomoCitJED levels greater than twice the cut-
off.  Thirty-six of 137 (26%) RA patients were negative for both anti-CCP2 and/or RF.  
In this latter subpopulation, 12/36 (33%) of RA patients expressed anti-CitJED and/or 
anti-HomoCitJED; 2/36 (6%) only expressed anti-CitJED, 2/36 (6%) only expressed anti-
HomoCitJED and 8 expressed both antibodies). 
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Figure 2.2. Serum anti-CitJED and anti-HomoCitJED levels are correlated in RA. 
Correlation graph comparing serum anti-CitJED and anti-HomoCitJED concentrations of 
RA patients (n=137).  The levels of IgG anti-CitJED and anti-HomoCitJED antibodies 
were compared by Spearman nonparametric correlation. 
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Figure 2.3. Anti-CitJED and anti-HomoCitJED are found in anti-CCP2 positive and anti-CCP2 negative RA patients. 
Frequency and percentage of anti-CitJED and anti-HomoCitJED subpopulations in anti-CCP2 positive RA patients (A) and anti-CCP2 
negative RA patients (B). 
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2.3.3 Cross-reactivity of anti-CitJED and anti-HomoCitJED 
antibodies 
To examine the cross-reactivity of anti-CitJED and anti-HomoCitJED, we performed 
inhibition ELISAs on RA sera (Figure 2.4) which met required anti-CitJED levels of 10 
AU/mL and/or anti-HomoCitJED levels of 70 AU/mL as described in Materials and 
methods.  We examined 15 anti-CCP2 positive and 2 anti-CCP2 negative RA patients 
that expressed both anti-CitJED and anti-HomoCitJED (referred to here as double 
positive) (Figure 2.4A, Figure 2.4B, Appendix 1, and Appendix 2)  We also examined 5 
patients that were anti-CitJED positive but anti-HomoCitJED negative (anti-CitJED 
single positive) (Figure 2.4C and Appendix 3) and 5 patients who were anti-HomoCitJED 
positive but anti-CitJED negative (anti-HomoCitJED single positive) (Figure 2.4D and 
Appendix 3).  These single positive patients were also positive for anti-CCP2.  None of 
the sera from single positive patients who were anti-CCP2 negative met the required 
antibody concentrations for the inhibition assay.   
 Anti-CitJED and anti-HomoCitJED from double positive and single positive RA patients 
were inhibited by both CitJED and HomoCitJED peptides (Figure 2.4).  The binding 
affinity for CitJED and HomoCitJED peptides was examined by comparing the peptide 
concentrations of CitJED and HomoCitJED required to achieve 50% inhibition of 
antibody reactivity.  The cognate peptide produced significantly greater inhibition of 
antibody reactivity (p<0.0001; Figure 2.4).  In double positive and anti-CitJED single 
positive RA patients, inhibition exceeding 50% of anti-CitJED binding activity required 2 
μg/mL of CitJED on average, compared to 100 μg/mL for HomoCitJED (Figure 2.4A and 
Figure 2.4C).  Anti-CitJED from 2/5 anti-CitJED single positive patients showed little to 
no inhibition by HomoCitJED (Appendix 3).  In double positive RA patients, inhibition 
of 50% of anti-HomoCitJED binding activity required 10 μg/mL of HomoCitJED 
compared to 50 μg/mL for CitJED (Figure 2.4B).  In the group of anti-HomoCitJED 
single positive patients, 50% inhibition of anti-HomoCitJED activity required 50 μg/mL 
of HomoCitJED compared to 100 μg/mL of CitJED (Figure 2.4D).  These results indicate 
that anti-CitJED and anti-HomoCitJED antibodies are cross-reactive, and have a higher 
inferred binding affinity to their respective cognate peptide. 
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Figure 2.4. Anti-CitJED and anti-HomoCitJED from anti-CCP2 positive and anti-CCP2 negative RA patients are cross-
reactive.  Average inhibitions of anti-CitJED (A) and anti-HomoCitJED (B) from 15 anti-CCP2 positive and 2 anti-CCP2 negative 
RA patients who were positive for both anti-CitJED and anti-HomoCitJED.  Average inhibitions of anti-CitJED from 5 anti-CitJED 
single-positive RA patients (C) and average inhibitions of anti-HomoCitJED from 5 anti-HomoCitJED single-positive RA patients 
(D). Anti-CitJED and anti-HomoCitJED single-positive RA patients had anti-CCP2.  ELISA plates were coated with 20 μg/mL 
(2ug/well) of CitJED (A,C) or HomoCitJED (B,D).  p<0.01 was considered significant by Two-way ANOVA. 
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2.4 Discussion 
In this study, we used synthetic citrullinated and homocitrullinated peptides, containing 
equal numbers of citrulline or homocitrulline residues, to examine the expression pattern 
and cross-reactivity of ACPA (represented by anti-CitJED) and AHCPA (represented by 
anti-HomoCitJED) in RA patients. We found that antibodies reactive to CitJED, and 
HomoCitJED, were frequently expressed in the serum of RA patients.  These antibodies 
were rarely found in healthy individuals and in patients with SLE or PsA.  The expression 
of anti-CitJED and anti-HomoCitJED antibodies was 77% concordant.  Additionally, we 
have demonstrated that anti-CitJED and anti-HomoCitJED are frequently cross-reactive 
in the patients studied and have higher affinity for the cognate peptide. 
We detected IgG anti-HomoCitJED antibodies in 57% of RA patients, a higher 
proportion than what was reported for other antibodies targeting homocitrullinated 
proteins or peptides (19-45%) (8,17–19,25–27).  Similarly, IgG anti-HomoCitJED was 
expressed in a significant proportion (28%) of anti-CCP2/RF negative RA patients.  
Antibodies to homocitrullinated proteins and peptides have been previously reported in 
anti-CCP2-negative RA patients to varying degrees (8,18,25–27).  This variability may 
be attributed to several factors, including differences in the characteristics of the study 
populations (genetics, environmental exposures and disease activity).  Consistent with a 
prior study, we did not observe a significant difference in IgG anti-HomoCitJED 
expression between RA patients with and without a history of smoking (data not shown) 
(25).  Our RA population had longer disease duration compared to the other studies and 
therefore may have developed more AHCPA reactivity over time.  We have also found 
that IgG anti-HomoCitJED were rarely found in healthy individuals and patients with 
SLE or PsA.   The specificity of IgG anti-HomoCitJED for RA requires further study 
with other types of inflammatory conditions.  Some studies have identified antibodies to 
carbamylated fetal calf serum (anti-CarP-FCS) in other inflammatory arthritides and 
connective tissue diseases (in up to 50% of patients) (26–30). 
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Prior studies did not examine the extent and affinity of antibody cross-reactivity of 
antibodies to citrullinated or homocitrullinated peptides, leading to the question of 
whether ACPA and AHCPA are part of a single antibody family or 2 separate antibody 
systems.  We performed detailed inhibition experiments, allowing for analyses of the 
prevalence and affinity of cross-reactive ACPA and AHCPA.  Using CitJED and 
HomoCitJED peptides which have equal numbers of citrulline and homocitrulline 
residues respectively, we observed that anti-CitJED and anti-HomoCitJED antibodies 
were inhibited by both peptides in the majority of RA patients (25/27 of RA patients 
examined by inhibition ELISA), including those who were positive for only one of these 
antibodies by direct ELISA.  The difference in antibody peptide-binding activity 
observed between direct ELISA and inhibition ELISA could be caused by lower peptide 
concentrations used in direct ELISA, or possibly due to conformational differences 
between soluble peptides and plate-bound peptides.  These results suggest significant 
cross-reactivity between ACPA and AHCPA and support the notion that these antibodies 
are part of the same antibody family, as proposed by Reed et al (19).  Cross-reactivity to 
citrullinated and homocitrullinated antigens has also been demonstrated in experimental 
animals.  Turunen et al. showed that immunization with homocitrullinated antigens led to 
the development of anti-citrulline reactivity in rabbits (15).  Furthermore, Mydel et al. 
observed the development of erosive arthritis in mice, immunized with a 
homocitrullinated filaggrin peptide followed by the introduction of citrullinated filaggrin 
peptide into the knee (31). 
In RA, it is not known whether citrullinated or homocitrullinated antigens (or both) are 
responsible for the initiation of autoantibody development.  ACPA and AHCPA have 
been detected in patients years prior to disease onset (6,10,11,32).  Furthermore, the anti-
citrullinated protein antibody response has been demonstrated to undergo epitope 
spreading, resulting in an expansion of the ACPA repertoire over time (32).  Because of 
the structural similarity between citrulline and homocitrulline, epitope spreading may 
lead to ACPA acquiring AHCPA specificities or vice versa.  We observed that the degree 
of cross-reactivity varied between RA patients with the majority having higher affinity 
for the cognate antigen. This finding likely reflects the abundance of the cognate antigen, 
which drives B cell maturation towards the production of higher affinity antibodies to the 
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same antigen.  We identified 2 patients that did not have cross-reactive antibodies who 
were both anti-CitJED positive, however, we did not determine whether these patients 
would later develop cross-reactivity to homocitrulline.  
There are limitations to this study: measurements were performed at one time point, few 
patients had early disease and samples from pre-RA subjects were not available.  Future 
longitudinal studies of early and pre-RA patients could provide a better understanding of 
the role of anti-homocitrulline and anti-citrulline antibodies in the initiation and 
progression of RA.  Detailed clinical information was also not available; therefore, we 
could not assess the impact of the cross-reactivity and affinity of these antibodies on RA 
disease activity and severity. 
In conclusion, antibodies to HomoCitJED and CitJED were frequently found in RA 
patients and were rare in other conditions. These findings demonstrate the immunologic 
relatedness of ACPA and AHCPA as detected by assays using CitJED and HomoCitJED 
peptides with equal numbers of citrulline and homocitrulline residues, and suggest that 
these antibodies are potentially derived from the same B cell population.  Cross-reactive 
B cells may provide a mechanism by which AHCPA are involved in RA pathogenesis. 
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Chapter 3  
3 Immune responses to peptides containing 
homocitrulline or citrulline in the DR4-transgenic mouse 
model of rheumatoid arthritis 
This chapter has been prepared for submission to The Journal of Autoimmunity. 
3.1 Introduction 
RA is characterized by the production of autoantibodies that target citrullinated 
proteins/peptides (ACPA).  Clinically, the most commonly measured ACPA is anti-cyclic 
citrullinated peptide antibodies (anti-CCP2), which are highly specific for RA (1,2) and 
predictive of erosive joint disease (3,4).  The susceptibility to ACPA-positive RA is 
significantly higher in individuals expressing HLA alleles (5,6) that encode a consensus 
sequence called the Shared Epitope (SE) (7).  The SE binds to peptides containing 
citrulline with high affinity initiating citrulline-specific T and B cell responses (8,9).  
Target antigens for these immune responses are present in the joint, including 
citrullinated fibrinogen (10), α-enolase (11,12), vimentin (13,14) and collagen II (15).  
Evidence suggests that ACPA bind to these targets in the joint leading to complement 
activation and chronic inflammation (16).  Experiments done in animal models further 
support the notion that T and B cell citrulline-specific immune responses are pathogenic 
(17–20). 
It is known that some ACPA also bind peptides or proteins containing homocitrulline 
(21–24), an amino acid that is structurally related to citrulline and is also present in RA 
synovium (25,26).  Antibodies to homocitrullinated antigens (also referred to as anti-
carbamylated antibodies (anti-CarP)) have been detected in the sera of RA patients 
(21,27–30) and are associated with more severe disease (27,31).  In silico evidence 
suggests that homocitrullinated peptides can be accommodated within the binding groove 
of the SE (21).  However, the relationship between the SE and homocitrullinated peptides 
remains unclear.  When immunized with homocitrullinated filaggrin-derived peptides and 
given an intra-articular injection of citrullinated peptide, different strains of mice 
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developed arthritis with varying frequency, suggesting that the MHC-H2 haplotype 
influences the development of arthritis (32).  The objective of this study was to examine 
the role of the SE in the development of immune responses to a peptide containing 
homocitrulline using a humanized SE-expressing DR4-transgenic mouse model of RA. 
3.2 Materials and methods 
3.2.1 Antigens 
The antigens used in this study were Citrullinated JED (CitJED) (21,33,34) and 
Homocitrullinated JED (HomoCitJED),  which are synthetic cyclic peptides containing 
18 amino acids with 9 residues of citrulline and homocitrulline, respectively.  These 
peptides were synthesized by Creative Peptides (Shirley, NY, USA).  Human fibrinogen 
(VWR) was left unmodified or was citrullinated or homocitrullinated for the antibody 
assays.  Citrullination of fibrinogen was previously described by Hill et al (35) and 
homocitrullination was performed as per the method of Scinocca et al (21). 
3.2.2 Mice and immunizations 
DR4-IE transgenic mice deficient in endogenous MHC class II on the C57Bl/6 
background (referred to as DR4tg)  (17,36) were bred in house.  C57Bl/6 mice (B6) mice 
were purchased from The Jackson Laboratory (Maine, USA).  Both strains of mice were 
housed in pathogen-free conditions at the Animal Care and Veterinary Services barrier 
facility at the University of Western Ontario as per the Canadian Council on Animal Care 
guidelines.  The study was approved by the Animal Care and Use Committee (The 
University of Western Ontario, London ON, Canada).  Female and male DR4tg and B6 
mice were immunized and boosted 21 days later with 100 μg of HomoCitJED suspended 
in PBS or PBS alone using the method of Hill et al (17).   
3.2.3 Splenocyte proliferation 
The splenocyte proliferation assay was adopted from Hill et al (17).  In brief, splenocytes 
were harvested from mice sacrificed at various time points and cultured in complete 
RPMI media (Gibco) at a concentration of 4 x 105 splenocytes/well.  Splenocytes were 
treated with 100 μg/mL of CitJED, HomoCitJED, or no peptide and incubated for 54 
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hours at 37°C, 5% CO2.  One μCi of 3H-thymidine was added to each well and incubated 
for an additional 18 hours.  Splenocytes were harvested using a Harvester96 (Tomtec) 
and radioactivity was measured with a MicroBeta JET (Perkin Elmer).  Proliferation 
experiments were conducted at least in quadruplicate and replicate counts per minute 
(cpm) were averaged (<20% intra-assay variation).  Proliferative responses are reported 
as a Stimulation Index (SI; cpm of samples with peptide/cpm of samples with media 
alone) +/- standard error of the mean.  A cut-off value of 2.0 was considered a positive 
proliferative response.  
3.2.4 Antibody assays 
Sera from mice at various time points were screened for IgG anti-HomoCitJED, anti-
CitJED, anti-citrullinated fibrinogen (anti-CitFib), anti-homocitrullinated fibrinogen 
(anti-HomoCitFib), anti-fibrinogen (anti-Fib) and anti-cyclic citrullinated peptide (anti-
CCP2) antibodies by direct antibody-binding ELISA.  HomoCitJED and CitJED were 
dissolved in 15% HCl in sterile distilled water.  The 15% HCl did not alter the structure 
of CitJED or its binding properties (data available upon request).  The protocol for anti-
HomoCitJED and anti-CitJED direct antibody-binding ELISA was similar to Hill et al 
(35) with the following modifications: wells were coated with 20 μg/mL of HomoCitJED 
or 40 μg/mL of CitJED in carbonate coating buffer, and 100 μL/well of biotin-conjugated 
goat anti-mouse IgG (1:5000; Jackson) with streptavidin horseradish peroxidase polymer 
(1:4000; Abcam) were used for antibody detection.  The ELISA protocol for anti-CitFib, 
anti-HomoCitFib and anti-Fib was also adapted from Hill et al (35) as described above, 
but 10 μg/mL of CitFib, HomoCitFib and Fib in carbonate coating buffer were used 
instead of the peptides.  These ELISAs were performed twice for each serum sample and 
the average OD was reported (<20% inter-assay variation).  The detection of anti-CCP2 
antibodies in mouse sera was performed using an anti-CCP2 ELISA kit (Euroimmun).  
The manufacturer’s protocol was followed with the exception that peroxidase-conjugated 
rabbit anti-mouse IgG (1:5000, Dako) was used.  The optical density was determined at 
450 nm.  The cut-off value for anti-CCP2 was 0.38 OD equal to two standard deviations 
above the mean value for PBS-immunized B6 mice.  The cut-off values for the other 
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antibodies were 0.1 OD, which is the lower detection limit of the ELISA (the mean 
values for these antibodies in PBS immunized mice were below 0.1).   
The cross-reactivity of IgG anti-HomoCitJED, anti-CitJED, and anti-CCP2 antibodies 
was examined by inhibition ELISA.  The protocol was adapted from Scinocca et al (21) 
with the following plate-bound antigens: CitJED, HomoCitJED and CCP2.  Inhibitions 
were performed with soluble CitJED and HomoCitJED at various concentrations (2 to 
100 μg/mL).  The average percent inhibition of two repeat determinations is reported, 
except for CCP2 that was performed once due to insufficient quantity of sera.  A 
minimum OD of 0.5 by direct antibody-binding ELISA was required to obtain a dose-
dependent, reproducible inhibition.   
3.2.5 Statistical analysis 
Graphpad Prism 6.0 software was used for data analysis.  The Mann-Whitney U test was 
used to compare SI or OD between DR4tg and B6 mice at the indicated time points 
(p<0.05 was considered significant).  Two-way ANOVA with Bonferonni correction was 
used for statistical analysis of inhibition experiments (p<0.01 was considered significant). 
3.3 Results 
3.3.1 Splenic T cell proliferative responses 
Splenocytes from DR4tg and B6 mice were assessed for proliferative responses to 
HomoCitJED and CitJED peptide by 3H-thymidine incorporation assay.  In DR4tg mice, 
HomoCitJED-specific splenocyte proliferative responses were observed as early as day 
10 in 3/7 (43%) of mice post-immunization with HomoCitJED.  These responses 
increased at later time points with 9/11 (82%) of mice having a significant proliferative 
response to HomoCitJED at day 100 (Figure 3.1A).  We also monitored DR4tg mice for 
T cell proliferative responses to CitJED peptide (Figure 3.1B).  Proliferation to CitJED 
was observed mainly in mice at day 100, with splenocytes from 8/9 (89%) of mice 
proliferating in response to CitJED stimulation.  In DR4tg mice immunized with PBS, 
HomoCitJED-specific T cell proliferation was not detected, but CitJED-specific T cell 
proliferation was detected in 2/9 (22%) at 100 days; the proliferative responses to CitJED 
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Figure 3.1. Splenocyte proliferative responses in DR4tg () and B6 () mice.  Splenocytes isolated from HomoCitJED-
immunized mice were cultured in the presence of 100 μg/mL of HomoCitJED (A) or CitJED (B).  Splenocyte proliferation, 
determined by 3H-thymidine incorporation at the days indicated, is shown as a mean stimulation index (± the SEM).  Stimulation 
indices greater than 2.0 (dashed line) were considered as a positive proliferative response.  ** - p<0.01 by the Mann-Whitney U test.  
Each symbol represents one mouse; n=5-11. 
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were significantly lower in PBS-immunized DR4tg mice compared to HomoCitJED-
immunized DR4tg mice (p<0.05; data not shown). 
To determine whether T cell responses to HomoCitJED and CitJED were restricted to 
SE-expressing DR4tg mice, we also examined the splenocyte proliferative response in B6 
mice which lack the SE.  HomoCitJED-immunized B6 mice developed HomoCitJED-
specific T cell responses, however these appeared only at day 100 in 4/9 (44%) of mice 
(Figure 3.1A).  These mice did not have CitJED specific T cell responses (Figure 3.1B).  
Splenocytes from PBS-immunized B6 mice did not proliferate to either peptide (data not 
shown). 
3.3.2 Antibodies to citrulline- and homocitrulline-containing 
antigens in DR4tg and B6 mice 
Sera from DR4tg and B6 mice were screened for the presence of various antibodies 
targeting citrullinated and homocitrullinated proteins or peptides (Figure 3.2).  In DR4tg 
mice immunized with HomoCitJED, anti-HomoCitJED antibodies were detected in a 
small proportion (6/22, 27%) of mice at day 10 post-immunization, followed by an 
increase in anti-HomoCitJED antibody expression at subsequent time points (Figure 
3.2A).  The peak of anti-HomoCitJED activity occurred at day 70, at which time 11/11 
(100%) of DR4tg mice were positive for these antibodies.  The expression of anti-
HomoCitFib antibodies (Figure 3.2B) also occurred in a similar pattern over time (the 
concordance of anti-HomoCitJED and anti-HomoCitFib antibodies was 86%).  
Antibodies to citrullinated peptides were present at later time points (day 50 and 70 post-
immunization) with 7/11 (64%) of mice expressing anti-CitJED and 8/11 (73%) 
expressing anti-CCP2 antibodies at day 70 (Figure 3.2C and Figure 3.2D).  Moreover, 
anti-CitJED and anti-CCP2 were concordantly expressed in 88% of DR4tg mice.  There 
were no detectable antibodies to CitFib and only 1 mouse had a low antibody response to 
Fib (data not shown).  All DR4tg mice that had antibodies targeting citrullinated peptides 
also expressed anti-HomoCitJED antibodies.     
In B6 mice immunized with HomoCitJED, antibody responses to HomoCitJED and 
HomoCitFib were observed at a later time point compared to DR4tg (day 100) in 4/9 
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Figure 3.2. Antibody responses in DR4tg () and B6 () mice.  Sera from HomoCitJED-immunized mice were screened for the 
presence of anti-HomoCitJED (A), anti-homocitrullinated fibrinogen (B), anti-CitJED (C), and anti-CCP2 (D) antibodies at the time 
points indicated post-immunization.  Antibody levels, determined by direct ELISA, are shown as the mean optical density (± the 
SEM).  Optical densities above the cut-off value are indicated by the dashed line.  The cut-off values were 0.38 for anti-CCP2 and 0.1 
for the other antibodies.  * - p<0.05, ** - p<0.01, *** - p<0.001, **** - p<0.0001 by the Mann-Whitney U test.  Each symbol 
represents one mouse; n=6-22. 
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(44%) and 2/9 (22%) mice, respectively (concordance = 71%; Figure 3.2A and Figure 
3.2B).  These B6 mice did not respond to citrullinated antigens except for one mouse that 
had a low response (Figure 3.2D).  PBS-immunized B6 or DR4tg mice did not have 
significant antibody responses to any of the antigens tested (data not shown).   
3.3.3 Antibody cross-reactivity in DR4tg and B6 mice 
To examine anti-CitJED and anti-HomoCitJED antibody cross-reactivity, antibodies from 
DR4tg mouse sera were inhibited with soluble CitJED and HomoCitJED peptides.  We 
inhibited IgG anti-HomoCitJED from 8 DR4tg mice that had anti-HomoCitJED 
antibodies, but lacked anti-CitJED based on direct ELISA (Figure 3.3A).  In these mice, 
anti-HomoCitJED antibodies were efficiently inhibited by cognate HomoCitJED peptide.  
However, two patterns emerged when these antibodies were inhibited with CitJED 
(Appendix 4).  In 5/8 mice, anti-HomoCitJED were not inhibited by CitJED, which 
suggests that these antibodies were HomoCitJED-specific.  In the other 3 mice, antibody 
reactivity to HomoCitJED was significantly inhibited by CitJED peptide, indicating that 
anti-HomoCitJED antibodies in these mice were cross-reactive.  Antibodies from serum 
collected at various time points (days 10-70 post-immunization) were tested in the 
inhibition assays; antibody cross-reactivity did not appear to be influenced by the time at 
which it was measured (Appendix 4).   
In DR4tg mice that expressed both anti-HomoCitJED and anti-CitJED antibodies by 
direct ELISA, anti-HomoCitJED antibodies were inhibited by HomoCitJED, but were not 
inhibited by CitJED (Figure 3.3B and Appendix 5A-C).  However, anti-CitJED 
antibodies from the same three mice were inhibited by both HomoCitJED and CitJED 
peptide (Figure 3.3C and Appendix 5D-F).  Anti-CitJED in these mice was inhibited 
more efficiently by the non-cognate peptide, HomoCitJED (p<0.0001). 
We also examined the antigen specificity of anti-CCP2 antibodies in DR4tg mice (Figure 
3.4).  Similar to anti-CitJED, anti-CCP2 antibodies were always co-expressed with anti-
HomoCitJED in DR4tg mice (n=4). Anti-CCP2 antibodies from 3/4 mice were efficiently 
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Figure 3.3. Inhibition of anti-HomoCitJED (black bars) and anti-CitJED (grey bars) antibodies.  Sera from HomoCitJED-
immunized DR4tg mice were used in inhibitions assays.  As measured by direct ELISA, these mice expressed anti-HomoCitJED 
antibodies but not anti-CitJED antibodies (n=8; A) or were positive for both anti-HomoCitJED and anti-CitJED antibodies (n=3; B, 
C).  The mean percent inhibition (pooled from inhibitions performed on n=3 or 8 mice) ± the SEM is shown.   * - p<0.0001 by Two-
way ANOVA with Bonferonni correction. 
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Figure 3.4. Inhibition of anti-CCP2 antibodies.  Sera from four HomoCitJED-immunized DR4tg mice (DR4tg #12-15; A-D) were 
used in inhibition assays at the indicated days post-immunization.  As detected by direct ELISA, these mice expressed anti-CCP2 
antibodies.  The percent inhibition from one experiment per individual mouse serum is shown.  
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inhibited by HomoCitJED peptide (Figure 3.4 A-C).  Two of these mice had anti-CCP2 
antibodies that were also inhibited by CitJED (Figure 3.4A and Figure 3.4B).  In one 
mouse, anti-CCP2 antibodies were not efficiently inhibited by either CitJED or 
HomoCitJED (Figure 3.4D). 
To determine whether antibody cross-reactivity was affected by the SE, we also inhibited 
anti-HomoCitJED from four B6 mice (Figure 3.5).  By direct ELISA, these mice 
expressed anti-HomoCitJED, but were negative for anti-CitJED and anti-CCP2 
antibodies.  In these mice, anti-HomoCitJED antibodies were inhibited by HomoCitJED 
peptide; there was no difference in the relative affinity of anti-HomoCitJED antibodies 
for HomoCitJED in B6 compared to DR4tg mice (Appendix 6).  However, anti-
HomocitJED antibodies from B6 mice were not inhibited by CitJED peptide.  Thus, 
unlike antibodies from DR4tg mice, anti-HomoCitJED antibodies from B6 mice were not 
cross-reactive. 
3.4 Discussion 
In this study, we immunized DR4tg and B6 mice with a synthetic homocitrullinated 
peptide, HomoCitJED and examined the development of splenic T cell proliferative and 
antibody responses to homocitrullinated and citrullinated peptides and proteins.  In 
DR4tg mice that expressed the SE and were immunized with HomoCitJED, we detected 
the early development of splenocyte proliferative and antibody responses to 
HomoCitJED.  These mice also generated antibodies to HomoCitFib, an antigen shown to 
be present in the RA synovium (26).  Anti-HomoCitJED antibodies from DR4tg mice 
also bound citrullinated antigens (CitJED and CCP2), supporting the notion that these 
antibodies are cross-reactive. 
It is known that there is a strong association between the SE and anti-citrullinated 
protein/peptide antibodies (ACPA) in RA patients (5).  Studies have shown that the SE 
binds citrullinated peptides with high affinity, initiating T and subsequently B cell 
responses (8,9).  In DR4tg mice, but not B6 mice, immunization with citrullinated 
fibrinogen causes arthritis suggesting that the SE is necessary for arthritis development 
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Figure 3.5. Inhibition of anti-HomoCitJED from B6 mice.  Inhibition assays were performed on sera from four HomoCitJED-
immunized B6 mice (B6 #1-4; A-D) at day 100 post-immunization.  As measured by direct ELISA, these mice expressed anti-
HomoCitJED antibodies but lacked both anti-CitJED and anti-CCP2 antibodies.  The mean percent inhibition of 2 repeats per 
individual mouse serum ± the SEM is shown.  * - p<0.0001 by Two-way ANOVA with Bonferonni correction. 
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 (17,20).  The chemical structure of homocitrulline is identical to citrulline except for one 
carbon atom; however, the affinity of homocitrullinated peptides for the SE and its effect 
on the immune response is unknown.  Moreover, the association between the SE and anti-
CarP was not found in a study of RA patients from Northern Europe (29).  The 
association between the SE and other anti-homocitrullinated protein/peptide antibodies 
(AHCPA) in other populations has not been previously studied.  Immune responses to 
homocitrullinated antigens occur in mice expressing different MHC-H2 alleles (32).  Our 
study is the first to use mice that express the SE and not endogenous mouse MHC class II 
molecules to study responses to homocitrulline and although we show that some B6 mice 
that express MHC-H2b did develop responses to homocitrullinated antigens, the DR4tg 
mice had earlier responses.  It is possible that I-Ab from B6 mice binds homocitrulline 
poorly.  In contrast, DR4 may be able to bind homocitrulline with high affinity, similar to 
citrulline (8,9), in its P4 binding pocket via the SE, accelerating T and B cell responses to 
homocitrullinated peptides.   
In addition to earlier T and B cell responses to homocitrullinated peptides and proteins, 
DR4tg mice immunized with HomoCitJED had sustained responses from day 10 to 100 
post-immunization.  Sustainability of an immune response may enhance epitope 
spreading (37), which is supported by our finding that DR4tg mice developed responses 
to citrullinated peptides and proteins at day 100 post-HomoCitJED immunization.  The 
ACPA responses from these mice had a higher inferred affinity by inhibition assays for 
HomoCitJED than CitJED, suggesting that the ACPA arise from B cell responses to 
HomoCitJED.  As in other studies showing that AHCPA are cross-reactive (21–24), some 
anti-HomoCitJED antibodies from DR4tg mice also bound CitJED.  Notably, B6 mice 
immunized with HomoCitJED did not develop antibodies to citrullinated antigens and 
anti-HomoCitJED antibodies from these mice did not bind CitJED, providing further 
evidence for the strong relationship between SE and citrullinated peptides. 
Our study has several other strengths.  We used a homocitrullinated peptide and its 
citrullinated counterpart that had the same backbone sequence and identical location and 
number of modified amino acids, minimizing the effect of the backbone on the 
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assessment of the immune response.  These synthetic peptides can act us surrogate 
antigens for an endogenously expressed modified protein (fibrinogen), known to be 
involved in the pathogenesis of RA (10,17,21,38).  The animal model we used is relevant 
to human RA in that the mice express the strongest genetic risk factor for this disease 
(39).  We describe the immune responses in these mice over an extended period of time.  
Detailed inhibition analyses were performed to examine the relative affinity of the anti-
HomoCitJED and anti-CitJED antibodies from these mice.  Unfortunately, we were 
unable to perform more extensive inhibition with other antigens due to insufficient sera 
volume.  Another limitation is that we did not continue our experiments past day 100 
post-immunization at which time the DR4tg mice immune responses started to decline, 
while in B6 mice, they were first detected.     
In conclusion, this study revealed that HomoCitJED is immunogenic leading to T and B 
cell responses to homocitrullinated antigens in SE-expressing DR4tg mice, which later 
evolve into immune responses to citrullinated antigens.  This evolution appears to be 
driven by epitope spreading rather than de novo generation of citrullinated antigens and 
relies on the SE.  These mice did not develop arthritis, however, in other animal models, 
arthritic mice expressed antibodies to homocitrullinated antigens (40).  Future work will 
assess the arthritogenic properties of anti-homocitrulline immune responses in the DR4tg 
mouse model. 
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Chapter 4  
4 Discussion 
4.1 Summary 
In this study, the objectives were to investigate the anti-homocitrulline as well as the anti-
citrulline immune responses in RA patients and in a mouse model of RA (DR4tg and B6 
mice).  The major findings in chapter 2 were that anti-HomoCitJED and anti-CitJED 
antibodies were frequently and specifically detected in RA patients.  These two 
antibodies were co-expressed in RA patients and were cross-reactive.  In chapter 3, 
DR4tg and B6 mice were immunized with HomoCitJED and the immune responses to 
HomoCitJED were examined.  Anti-homocitrulline immune responses were shown for 
the first time to be associated with the SE.  These responses could also occur in the 
absence of the SE but the development of cross-reactive anti-citrulline responses only 
occurred in DR4tg mice.  
4.2 Anti-homocitrulline antibodies are specifically 
associated with RA and are cross-reactive to citrulline 
Anti-homocitrulline antibodies are a family of antibodies that have been recently 
associated with RA.  However, some aspects of these antibodies, including the 
prevalence of these antibodies in RA patients, their specificity for disease, as well as their 
relationship with anti-citrulline antibodies are not well understood.  The studies that have 
been performed thus far on anti-homocitrulline and anti-citrulline cross-reactivity are few 
in number and have used different homocitrulline-containing antigens with limited 
specificity (1–6).  Thus, a major strength of this study was the use of a novel, 
homocitrulline-rich peptide (HomoCitJED) as a surrogate target of anti-homocitrulline 
antibodies in RA patients (ie. designed with the potential to detect anti-homocitrulline 
antibodies to numerous homocitrullinated antigens).  CitJED, the citrulline-containing 
counterpart of HomoCitJED, was used for the detection of anti-citrulline antibodies.  
These peptides allowed for the examination of antibody reactivity (and cross-reactivity) 
to homocitrulline and citrulline.   
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The antibody responses to HomoCitJED and CitJED were evaluated for their specificity 
for RA.  Another strength of this study design was the use of patients with other 
inflammatory conditions as the most appropriate controls.  The presence of anti-
HomoCitJED and anti-CitJED antibodies was examined in sera from patients with PsA, 
an inflammatory joint disorder that shares many clinical features with RA but are not 
associated with autoantibody expression (7).  Additionally, sera from patients with SLE, 
an inflammatory autoimmune disorder that is associated with the development of 
autoantibodies to DNA and ribonucleoproteins (8), were also screened for antibody 
activity to HomoCitJED and CitJED. 
Anti-CitJED antibodies were found to be specific for RA because they were not detected 
in healthy subjects, SLE patients, nor PsA patients.  This is in agreement with the 
literature that other anti-citrulline antibodies to CCP  (9–11), citrullinated fibrinogen (12) 
and mutated citrullinated vimentin (13) are highly specific for RA.  Previously, Reed et 
al. suggested that anti-homocitrulline antibodies could be a biomarker of inflammation 
instead of being specifically associated with RA (6).  However, this was not the case for 
anti-HomoCitJED as these antibodies were not detected in patients with other 
inflammatory conditions (PsA or SLE).   
Anti-HomoCitJED antibodies were detected in a large proportion of RA patients 
(approximately 60%), and were found to be expressed alongside anti-CitJED in many of 
these patients.  This is in agreement with the findings that the anti-CarP-FCS are 
frequently found in anti-CCP positive RA patients (1,14).  Anti-HomoCitJED and anti-
CitJED antibodies in patients that had both of these antibodies were inhibited by both 
HomoCitJED and CitJED peptides (cross-reactive).  In addition, a small proportion of 
RA patients were positive for anti-HomoCitJED but not anti-CitJED (15%) or the 
converse (8%) as measured by direct antibody ELISA.  However, anti-HomoCitJED and 
anti-CitJED from these patients were also inhibited by both HomoCitJED and CitJED.  
Thus, the evidence presented here indicates that anti-homocitrulline and anti-citrulline 
antibodies constitute a single, cross-reactive antibody population as proposed by Reed et 
al (6). 
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4.3 The SE is involved with anti-homocitrulline immune 
responses and cross-reactivity to citrulline 
This study examined the development of anti-homocitrulline and anti-citrulline immune 
responses in DR4tg mice.  This is a relevant model of RA because these mice express the 
SE, which is found in the majority of RA patients (15–17) and confers disease 
susceptibility (18).  DR4tg mice have also been shown to develop arthritis when 
immunized with citrullinated fibrinogen (19), an antigen that has been found to be present 
in the joints of arthritic DR4tg mice (19) as well as in the synovial tissue of RA patients 
(20). 
The T and B cell responses following immunization with HomoCitJED in mice with 
(DR4tg mice) and without the SE (B6 mice) were investigated to examine i) the 
development of anti-homocitrulline immune responses, ii) whether these immune 
responses were SE-dependent, and iii) the cross-reactivity of anti-homocitrulline 
responses to citrulline. 
Anti-HomoCitJED T and B cell responses were observed in both DR4tg and B6 mice.  
Additionally, antibodies to homocitrullinated fibrinogen could be detected in both mouse 
strains and were found to be concordant with anti-HomoCitJED.  The finding that anti-
homocitrulline responses can occur in the absence of the SE is in agreement with 
previous work by Mydel et al. (21), and suggests that  homocitrulline can be 
accommodated by some mouse MHC class II molecules, including I-Ab from B6 mice, 
resulting in anti-homocitrulline immune responses.  Nonetheless, this study provides the 
first in vivo evidence that the immune response to homocitrulline is SE-associated.  
A difference observed between DR4tg and B6 mice was that the immune responses in 
DR4tg mice were more frequent and occurred earlier.  This may indicate that SE-encoded 
HLA-DR molecules are better binders of homocitrulline-containing peptides compared to 
those without the SE.  Thus, antigen presentation in DR4tg mice may be more efficient in 
activating homocitrulline-specific T cells that help B cells to generate antibodies to this 
peptide.  
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The main difference between DR4tg mice and B6 mice was that immunization with 
HomoCitJED also led to the development of T cell responses to CitJED and antibodies to 
citrullinated peptides (CitJED and CCP) in (SE-positive) DR4tg mice.  These immune 
responses occurred later compared to the anti-homocitrulline immune responses in DR4tg 
mice.  Anti-citrulline antibodies were only found in mice that also had anti-HomoCitJED 
and were also cross-reactive to HomoCitJED.  This shows that the anti-homocitrulline 
immune response precedes the anti-citrulline response in mice and the same may occur in 
RA patients.  In contrast, anti-citrulline T and B cell responses were not detected in (SE-
negative) B6 mice in any of the assays used in this study.  This reinforces the idea that 
cross-reactivity between anti-homocitrulline and anti-citrulline immune responses is SE-
dependent. 
The anti-homocitrulline and anti-citrulline antibody responses in DR4tg mice shared 
similarities with the antibody responses that were observed in RA patients of this study.  
DR4tg mice expressed antibodies to HomoCitJED, CitJED and CCP following 
immunization with HomoCitJED, and similarly, these antibodies were also expressed by 
RA patients.  DR4tg mice developed anti-homocitrullinated fibrinogen antibodies, which 
have also been reported to be present in the same cohort of RA patients as used here 
(3,22).  Antibodies in both the DR4tg mice and RA patients were cross-reactive.  Not 
surprisingly, due to the differences in genetic makeup, cross-reactivity was observed in a 
different proportion of RA patients compared to DR4tg mice.  These observations, in 
addition to a previous study performed by the laboratory of Cairns and Bell (19), supports 
the use of the DR4tg mouse model for the study of mechanisms underlying the 
pathogenesis of RA.  
4.4 Homocitrulline plays a role in RA pathogenesis 
Autoimmunity involves the breakdown of immunological tolerance to self-tissues.  In RA 
patients, there is a loss of tolerance to citrullinated proteins as well as to 
homocitrullinated proteins.  This study provides evidence that homocitrulline is able to 
induce both anti-homocitrulline and cross-reactive anti-citrulline immune responses.  
This may be due to the structural similarity between homocitrulline and citrulline.  The 
combination of molecular mimicry, which exists when antigens share similar sequences  
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(23,24), and B cell cross-reactivity to these related antigens (23) have previously been 
described as driving factors in B cell epitope spreading.  Epitope spreading is the 
diversification of epitopes that are recognized by the immune system (23) and has been 
implicated in the development of autoimmune diseases including RA (23,25) and SLE 
(23,26).   
In RA, epitope spreading has been shown to cause an expansion in the repertoire of anti-
citrulline antibodies in patients prior to disease onset (25).  The findings in this study 
suggest that epitope spreading can also occur between the anti-homocitrulline and anti-
citrulline antibody responses and is dependent on the expression of the SE.  Additionally,  
B cells express MHC class II molecules and studies have shown that B cells are able to 
activate antigen-specific T cells in mouse models of RA (27,28).  Thus, cross-reactive B 
cells with SE-encoded HLA-DR may be able to present homocitrulline- or citrulline-
containing epitopes to T cells.  This could result in the propagation of immune responses 
to both homocitrulline and citrulline in RA patients and further exacerbate the 
autoimmune response in RA patients by promoting T cell activity. 
Currently, the mechanism underlying RA pathogenesis is believed to involve the 
presentation of citrullinated peptides by antigen presenting cells that express SE-encoded 
HLA-DR molecules to citrulline-specific helper T cells, as initially described by Hill et al 
(29).  These T cells subsequently activate citrulline-specific B cells, which then drive the 
production of anti-citrulline antibodies.  Evidence from this study suggests that 
homocitrulline can play a similar role (Figure 4.1).  Homocitrulline can be presented by 
SE-encoded HLA-DR molecules and result in cross-reactive anti-homocitrulline and anti-
citrulline antibodies.  These cross-reactive antibodies can then bind to either 
homocitrullinated or citrullinated antigens, which have been shown to be present in RA 
joint tissue (21,30,31), resulting in inflammation and RA development.  Thus, it is 
possible that homocitrulline plays a role in RA pathogenesis by contributing to the 
breakdown of self-tolerance to citrulline and vice-versa.  However it is not known 
whether homocitrulline or citrulline (or both) is responsible for RA development. 
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Figure 4.1. Immune responses to homocitrulline in RA.  Homocitrulline-containing 
peptides are presented by SE-encoded HLA-DR on antigen presenting cells (APC) 
resulting in T and B cell activation.  Activated B cells produce cross-reactive antibodies 
to homocitrulline and citrulline which mediate inflammatory responses in RA joint tissue. 
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4.5 Limitations and future directions 
This study examined the expression and cross-reactivity of anti-HomoCitJED and anti-
CitJED antibodies in RA patients with established (long-standing) disease.  It is possible 
that the longer disease durations allowed for the RA patients to develop more anti-
homocitrulline or anti-citrulline antibody activity over time (due to epitope spreading).  
To better understand the development of the anti-homocitrulline and anti-citrulline 
immune responses in RA patients, anti-HomoCitJED and anti-CitJED expression and 
cross-reactivity will need to be studied in patients with early disease and in patients prior 
to the onset of RA. 
The studies in mice revealed that anti-homocitrulline antibodies can be generated in the 
absence of the SE, but cross-reactivity to citrulline was dependent on the expression of 
the SE.  Whether this is the same in RA patients is unknown because the HLA haplotypes 
of the RA patients were not investigated.  Genotyping of RA patients will provide further 
insight on the association of anti-homocitrulline and anti-citrulline responses with the SE. 
Another limitation of this study was that the association between the SE and 
homocitrulline was demonstrated using functional assays (T and B cell responses to 
homocitrulline) in DR4tg mice.  Further studies which examine whether homocitrulline-
containing peptides can directly bind to SE-encoded HLA-DR molecules are required to 
confirm this finding. 
Additionally, the mouse studies were limited by the duration of the study period.  B6 
mice were found to not develop cross-reactive immune responses to citrulline at any of 
the time points examined.  However, the immune responses in B6 mice were detected at 
day 100 (the last day time point that was assessed).  It is possible that the B6 mice would 
later develop reactivity to citrulline.  Thus, studies over longer periods of time are 
required. 
In the DR4tg mouse model of RA, immunization with HomoCitJED did not induce 
arthritis.  A possible explanation for this finding, is that the DR4tg mice may not have 
expressed or expressed insufficient levels of homocitrulline (or citrulline) in their joints.  
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Future studies will involve the injection of homocitrullinated or citrullinated antigen into 
the knees of DR4tg mice, to provide a target for the immune response and to examine if 
this model can recapitulate the disease seen in RA patients.  
Furthermore, this study examined the development of cross-reactive immune responses to 
a homocitrulline-containing antigen (HomoCitJED).  It is unknown if cross-reactive 
immune responses to homocitrulline can develop from an anti-citrulline response.  Thus 
future studies will examine the induction of anti-citrulline and anti-homocitrulline 
responses in mice immunized with CitJED. 
4.6 Significance 
RA is an inflammatory joint disorder with an unknown etiology, but which is 
characterized by antibodies to proteins modified by citrullination.  RA patients also 
specifically express antibodies to a structural analog of citrulline, homocitrulline.  Using 
the homocitrulline- and citrulline-rich peptides, HomoCitJED and CitJED, this study 
demonstrates that anti-citrulline and anti-homocitrulline antibodies are cross-reactive to 
these two amino acids.  In addition, this study demonstrated the first in vivo evidence that 
the SE is associated with the initiation of immune responses to homocitrulline.  Further, 
the development of cross-reactive anti-citrulline and anti-homocitrulline immune 
responses are dependent on the expression of SE-encoded HLA-DR.  A novel mechanism 
is presented by which homocitrulline-containing antigens can induce a breakdown in 
immunological tolerance to citrullinated self-proteins.  Cross-reactive B cells to citrulline 
and homocitrulline play a role in propagating autoimmune responses and contribute to 
RA pathogenesis.  Thus homocitrulline may have an important role in RA development. 
Presently, there is no antigen-specific treatment for RA.  The current therapeutic 
strategies for RA include the use of immunosuppressants, cytokine inhibitors, and 
biologics that target components of the immune system and often have side-effects.  
Specific treatment options for RA are being explored.  One approach is the use of peptide 
vaccines, including citrullinated peptide vaccines, to induce antigen-specific immune 
tolerance (32-34).  HomoCitJED peptide may also be useful in this approach because this 
peptide could potentially block both anti-homocitrulline and anti-citrulline immune 
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responses in RA patients.  Pilot studies using HomoCitJED peptide to induce tolerance 
are ongoing in the Cairns and Bell laboratory. 
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Appendices 
  
Appendix 1. Anti-CitJED inhibition by CitJED and HomoCitJED peptides.  Anti-
CitJED inhibition profiles for 15 anti-CCP2 positive (A-O) and 2 anti-CCP2 negative (P-
Q) RA patients who expressed anti-CitJED and anti-HomoCitJED.  Antibodies were 
inhibited by various concentrations of either soluble CitJED or HomoCitJED peptide. 
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Appendix 2. Anti-HomoCitJED inhibition by CitJED and HomoCitJED peptides.  
Anti-HomoCitJED inhibition profiles for 15 anti-CCP2 positive (A-O) and 2 anti-CCP2 
negative (P-Q) RA patients (same RA patients as in Appendix 1) who expressed anti-
CitJED and anti-HomoCitJED.  Antibodies were inhibited by various concentrations of 
either soluble CitJED or HomoCitJED peptide. 
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Appendix 3. Most anti-CitJED and anti-HomoCitJED from single positive RA 
patients are cross-reactive.  (A-E) Inhibition of anti-CitJED from 5 anti-CitJED single 
positive RA patients.  (F-J) Inhibition of anti-HomoCitJED from 5 anti-HomoCitJED 
single positive RA patients.  All patients tested were positive for anti-CCP2; p<0.01 was 
considered significant by Two-way ANOVA.  n.s. – not significant.  
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Appendix 4. Inhibition of anti-HomoCitJED antibodies.  Sera from eight HomoCitJED-immunized DR4tg mice (DR4tg #1-8; A-
H) were used in inhibitions assays at the various days post-immunization as indicated.  As measured by direct ELISA, these mice 
expressed anti-HomoCitJED antibodies but not anti-CitJED antibodies.  The mean percent inhibition of 2 repeats per individual mouse 
serum ± the SEM is shown.  * - p<0.0001 by Two-way ANOVA with Bonferonni correction. 
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Appendix 5. Inhibition of anti-HomoCitJED (black bars) and anti-CitJED (grey bars) antibodies.  Sera from three 
HomoCitJED-immunized DR4tg mice (DR4tg #9-11; A-F), were used in inhibitions assays at the various days post-immunization as 
indicated.   As detected by direct ELISA, these mice were positive for both anti-HomoCitJED and anti-CitJED antibodies.  The mean 
percent inhibition of 2 repeats per individual mouse serum ± the SEM is shown.  * - p<0.0001 by Two-way ANOVA with Bonferonni 
correction. 
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Appendix 6. Inhibition of anti-HomoCitJED antibodies with HomoCitJED peptide.  Inhibition assays were performed on sera 
from HomoCitJED-immunized DR4tg and B6 mice.  As measured by direct ELISA, these mice expressed anti-HomoCitJED 
antibodies but not anti-CitJED antibodies. The mean percent inhibition (pooled from inhibitions performed on n=4 or 8 mice) ± the 
SEM is shown.   The p value was determined by Two-way ANOVA with Bonferonni correction. 
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Appendix 7. Ethical approval for the use of human samples.  
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Appendix 8. Ethical approval for the use of animal subjects.  
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